ERS/EU RESPIRE2 Fellowship funds research into therapeutic target in IPF

ERS/EU RESPIRE2 Fellowship funds research into therapeutic target in IPF - article image

ERS/EU Marie Curie RESPIRE2 Fellowship recipient, Dr Argyrios Tzouvelekis has had a research paper exploring the potential role of SHP2 (SH2 domain-containing-tyrosine phosphatase) as a therapeutic target in Idiopathic Pulmonary Fibrosis (IPF) published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).

Specifically, data suggests that SHP2 is an important regulator of fibroblast differentiation and its loss as observed in patients with IPF facilitates profibrotic phenotypic changes.

Dr Tzouvelekis is 1st author on the paper, which is the result of research undertaken alongside Dr Naftali Kaminski at Yale University in the USA. Thanks to co-funding by ERS and the EU as part of the RESPIRE2 Fellowship programme, this research is ongoing at Dr Tzouvelekis’ current host institution, the Biomedical Sciences Research Center, Alexander Fleming in Athens, Greece.

The objectives of the ERS/EU Marie Curie RESPIRE2 Fellowships are to support the most talented scientists, to strengthen the respiratory specialty, and to increase transnational mobility by enabling access to some of Europe's top centres. The Fellowship aims to enhance career development and scientific networks as well as to offer attractive post-doctoral funding and excellent working conditions.

The RESPIRE2 programme is ongoing and in the coming weeks ERS will launch a new opportunity to become a Marie Curie Fellow through the next-generation ERS/EU Marie Curie RESPIRE3 Fellowship. The first call will be announced in the ERS newsletter.